Bone metastases treatment can improve overall survival
Thursday, November 15, 2012 - 20:31
in Health & Medicine
One of the most frequent sites of metastases is the bone, with an estimated 30 to 40 percent of patients with non-small-cell lung cancer developing bone loss. A study shows that the bone metastases drug denosumab was associated with improved overall survival compared with zoledonic acid.